contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


antal-aktier-och-roster-i-oncopeptides-11

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Oncopeptides is a biotechnology company developing drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic agents into cancer cells. The company has drugs for commercialization, and has several drug candidates in development. Oncopeptides was founded in 2000 and is headquartered in Stockholm.

Oncopeptides AB is a Swedish biotech company that, after a long development phase, has successfully developed and commercialized a drug called Pepaxti. This drug is intended for use in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have not responded adequately to previous treatments. The company went public in 2017 and, as often happens with these early-stage companies, the share price has collapsed since the listing. The road toward phase III was a grim one for shareholders of this company as well. Now, however, we are in a situation where the drug has been commercialized. For a novice biotech investor, this is a situation where the focus can shift to marketing and cash flow, now that the drug is proven to work. In fact, the situation is ideal in the sense that the drug’s efficacy has now been established, and the focus is now on the company generating cash flow through this new drug. There aren’t many companies in this exact situation. Often, early-stage companies are dependent on funding rounds, or in the mature stage, patents are expiring and the concern is how price levels will crash as competition intensifies when generic drugs enter the market. I hope that this modest and brief introduction will nevertheless act like flypaper and attract this forum’s heavyweight biotech analysts to give their verdict on this company that has traveled such a long and hard road. A link to the company’s website is below, where there is naturally much more information about this company, which I believe definitely deserves a thread on the best investment portal in the Nordics.                   Oncopeptides              Start - English - Oncopeptides    Oncopeptides is a global biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat hematological diseases.

Oncopeptides

Stockholm – 31 mars 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), ett biotechbolag inriktat på att utveckla läkemedel mot svårbehandlade hematologiska sjukdomar, meddelar idag att ...

<div class="mfn-preamble"><p><strong>Stockholm – 31 mars 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), ett biotechbolag inriktat på att utveckla läkemedel mot svårbehandlade hematologiska sjukdomar, meddelar idag att antalet aktier och röster i Oncopeptides har ändrats till följd av företrädesemissionen som slutfördes den 16 mars 2026.</strong></p></div><div class="mfn-body"><p>Efter företrädesemissionen uppgår det totala antalet aktier i Oncopeptides till 395&nbsp;287 003 aktier, varav 381&nbsp;148 118 är stamaktier och 14&nbsp;138 885 är C-aktier. Efter företrädesemissionen uppgår det totala antalet röster i Oncopeptides till 382&nbsp;562&nbsp;006,5. Aktiekapitalet har ökat med 13&nbsp;620&nbsp;072,330911 kronor från 30&nbsp;300&nbsp;707,563894 kronor till 43&nbsp;920&nbsp;779,894805 kronor.</p></div><div class="mfn-footer mfn-contacts mfn-ad2e6a7e9211"><p><strong class="mfn-heading-1">För ytterligare information kontakta:</strong><br>David Augustsson, Kommunikations- och IR-chef, Oncopeptides AB (publ)<br>E-post: <a href="mailto:%20ir@oncopeptides.com" rel="noopener">ir@oncopeptides.com</a><br>Mobil: +46 76 229 38 68</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-lhfi"><p><em>Denna information är sådan information som Oncopeptides är skyldigt att offentliggöra enligt lagen om handel med finansiella instrument. Informationen lämnades för offentliggörande den 2026-03-31 08:30 CEST.</em></p></div><div class="mfn-footer mfn-about mfn-05abf943815f"><p><strong class="mfn-heading-1">Om Oncopeptides</strong><br>Oncopeptides är ett svenskt biotechbolag inriktat på forskning, utveckling och kommersialisering av riktade terapier för svårbehandlade cancersjukdomar.</p><p>Bolaget använder sin patenterade PDC-plattform för att utveckla peptidlänkade läkemedel som snabbt och selektivt levererar cellgifter in i cancerceller. Bolagets flaggskeppsläkemedel kommersialiseras för närvarande i Europa, med partnerskapsavtal för bland annat Sydkorea, Mellanöstern och Afrika.</p><p>Oncopeptides utvecklar flera nya läkemedelskandidater baserat på sina två patenterade teknikplattformar PDC och SPiKE.</p><p>Bolaget grundades år 2000, har ca 80 anställda och verksamhet i Sverige, Tyskland, Österrike, Italien och Spanien. Oncopeptides är noterat på Nasdaq Stockholm med förkortningen ONCO.</p><p>För mer information, se <a href="http://www.oncopeptides.com/sv/" rel="noopener">www.oncopeptides.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Bifogade filer</strong><br><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/efb3d800-7bfa-44ec-9034-a06f364f2ec8/antal-aktier-och-roster-i-oncopeptides.pdf" rel="noopener">Antal aktier och röster i Oncopeptides</a></p></div>